Fig. 1
Changes in CD4+ regulatory T cells (Treg), “effector” T cells (Teff), and Treg function in PBMC. a FACS gating strategy used to identify CD4 + CD25hiCD127lo/neg foxP3+ Tregs and CD4 + CD25 + CD127 + foxP3- Teff in PBMC (first four FACS plots, left to right) and in PBMC depleted of CD25+ Tregs (fifth FACS plot, right). b-e Illustrate changes over time at each study timepoint for each individual patient (open symbols), compared with baseline (M0) values. b Changes in Tregs. c Changes in Teff. d Changes in Teff:Treg ratio. e Changes in Treg function, indicated as percent rebound in CD25-depleted PBMC compared to undepleted PBMC. Data in all panels represent median/IQR values for all patients at each timepoint. p values indicate significant changes from baseline (M0) as follows: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05; mixed effects ANOVA with Tukey’s corrections for multiple comparisons